Muz rape victim, left waiting for hrs in ambulance, dies at PMCH
1
2
Patna: An 11-year-old Dalit girl from Muzaffarpur, who was brutally raped and stabbed, died at Patna Medical College Hospital (PMCH) on Sunday after being kept in a critical condition in an ambulance for more than four hours without admission on Saturday.
The child was assaulted on May 26 and stabbed multiple times in the neck, chest and abdomen. Doctors at SKMCH in Muzaffarpur referred her to PMCH after her condition deteriorated on Saturday. The accused, Rohit Sahni, in his 30s, has been arrested.
Her uncle alleged he was asked to pay Rs 2,000 for an oxygen cylinder when the supply ran low during transit. "Blood was coming out of her nose and mouth on Sunday morning, but no doctor came to see her," he said.
Her vocal cords were severely damaged with her throat partially slit by the accused.
Congress MP Ranjeet Ranjan told reporters in Delhi that SKMCH doctors initially recommended she be sent to AIIMS-Patna, but the administration refused, citing a shortage of specialists in ENT and gynaecology. "She died due to the apathy of the hospital administration," she alleged.
State Congress media cell chairman Rajesh Rathorre, who was at PMCH on Saturday with other party leaders, said the girl was left in the ambulance for hours and was only admitted after pressure from Congress workers.
"She didn't receive proper treatment," he said, questioning the govt's claim of developing PMCH into a world-class hospital.
In a viral video, the PMCH deputy superintendent claimed doctors from three departments were involved in her treatment. When told about the four-hour delay, he said emergency doctors had seen her.
Health minister Mangal Pandey was unavailable for comment.
This was the third instance of rape of a minor in Muzaffarpur's Kudhni area since May 26. Another 11-year-old was raped on Saturday, while in Vaishali, a teenager's body was found in a sack with a suspected sexual assault under investigation.
The Congress has launched a phased protest over the issue, burning effigies of CM Nitish Kumar and health minister Pandey in Patna on Sunday evening.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hans India
9 minutes ago
- Hans India
Kishan touts ESI Med College as the best hospital in country
Hyderabad: Union Minister Kishan Reddy visited the ESIC Hospital in Sanathnagar on Monday, where he reviewed the current conditions of the hospital across all departments. During his visit, hospital staff presented an overview of the new policies and medical services being provided to working families and patients through a screen presentation. Later, he inspected the construction work of the newly built building. Earlier in the day, he planted a sapling on the hospital premises. Addressing the media after the review, Kishan Reddy congratulated the hospital management and staff for receiving the award for being the best hospital in the country, recognising the achievements of the Sanath Nagar ESI Medical College and Hospital. He congratulated the hospital management and staff for their efforts. He said the hospital caters to approximately 3,000 outpatients daily, with around 900 patients visiting the super speciality hospital. The ESI Hospital is becoming a strong competitor to corporate hospitals, and there is a commitment to enhance its specialisation in various medical fields soon, including a focus on organ transplants. Telangana has registered 1.7 million ESI cards, allowing access to medical services for approximately 8 million people. Steps are being taken to facilitate online doctor appointments, in-home blood sampling, and mobile delivery of test results. A record 2,900 patients are currently visiting the outpatient department (OP). 'The Modi government is significantly boosting healthcare in Telangana; the Center has approved AIIMS, ESI, and two new medical colleges, which are already underway. A new medical college is under construction with an investment of Rs 800 crore, with 300 beds. It is set to open soon, alongside improvements in infrastructure using the latest technology. Thirty-five per cent of seats in the medical college have been reserved for Insured Persons (IP), with 1,027 students currently enrolled in the MBBS program. Over 3,000 MBBS graduates have already completed their studies. They are serving the community, while 44 students have completed MD and MS degrees and are providing medical services. Each year, 307 students graduate from various departments, with prestigious specialization courses available at the ESI Hospital and Medical College, he added. The institution offers Medical, Paramedical, MD, MS, MCh, and DNB programs education courses.
Business Standard
an hour ago
- Business Standard
Biocon gets CDSCO approval for Liraglutide drug substance
Biocon said that it has received an approval from the Drugs Controller General of India (DCGI), under the central drugs standard control organisation (CDSCO), for its Liraglutide drug substance. Additionally, its wholly owned subsidiary, Biocon Pharma, has received CDSCO approval for the Liraglutide drug product (6 mg/ml solution for injection in pre-filled pen and cartridge). The said approval is for the generic version of Victoza, indicated for the treatment of insufficiently controlled type 2 diabetes mellitus in adults, adolescents and children aged 10 years and above, as an adjunct to diet and exercise. The approval was received from the CDSCO under the recently formulated 101 route that enables recognition of approvals granted by established and referenced serious regulatory authorities. Siddharth Mittal, chief executive officer and managing director, Biocon, said: The approval of our first vertically integrated GLP-1 in India, Liraglutide, is another significant step forward in expanding access of this product to patients suffering from diabetes. India has one of the highest number of people with diabetes globally, with estimates exceeding 77 million cases, and expected to rise further. The approval enables us to address a critical need by making this drug available, and aligns with Biocons mission to provide affordable, lifesaving medications to those who need it the most. We are now gearing up to launch the product expeditiously through our commercialization partners in India. Biocon is an innovation-led global biopharmaceutical company focused on improving affordable access to complex therapies for chronic conditions like diabetes, cancer and autoimmune diseases. It has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets, as well as generic formulations in the U.S. and Europe The companys consolidated net profit surged 154.2% to Rs 344.50 crore on 12.8% jump in net sales to Rs 4,358.10 crore in Q4 FY25 over Q4 FY24. The counter shed 0.45% to end at Rs 334.05 on the BSE.
Hans India
an hour ago
- Hans India
Current Covid wave unlikely to strain hospitals
New Delhi: With India witnessing nearly 4,000 active Covid-19 cases, health experts have urged the public not to panic, stating that the current surge is unlikely to cause a higher burden on hospitals. As per the latest figures from the Ministry of Health, there are 3,961 active Covid cases. The number of deaths across multiple states, since January 1, 2025, surged to 32. Meanwhile, 2,188 patients were discharged or migrated in the last 24 hours, indicating an improvement in recovery. "It is highly unlikely that the current infection can cause a higher burden on the hospitals. Hence, there is no need to panic. However, the sentinel surveillance system needs to be strengthened in order to catch the outbreak in the earlier phase," says Dr Harshal R Salve, Additional Professor at the Centre for Community Medicine at AIIMS, New Delhi. States currently reporting the highest number of active infections include Kerala (1,435), Maharashtra (506), Delhi (483), Gujarat (338), and West Bengal (331). This fresh wave has been caused by two new coronavirus variants, NB.1.8.1 and LF.7, mutations of the Omicron offspring JN.1 variant. Both were found in India, as per data from the Indian SARS-CoV-2 Genomics Consortium (INSACOG), set up under the Ministry of Health.
